• Cancel
    Date：2022-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=725

    Worg Pharmaceuticals, a biopharmaceutical company dedicated to providing breakthrough immune therapy solutions, announced the successful closing of nearly RMB 400 million in its Series B financing. Investors in this round of funding included Junson Capita

  • Cancel
    Date：2022-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=727

    BoomRay Pharmaceuticals is at the forefront of creating next-generation targeted radionuclide-conjugated drugs. HongShan led this round, with participation from Riverhead Capital, Tririver Capital, Puhua Capital, Tsing Song Capital, Life Sciences Investme

  • Cancel
    Date：2022-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=728

    Raintech, a leading smart IoT production management platform for greenhouses, announced the successful closing of its Series A financing, with Shunwei Capital investing millions of RMB. The funds will be primarily used for product research and development

  • Cancel
    Date：2022-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=729

    Therorna Inc. is dedicated to the development of novel vaccines and therapies in multiple cutting-edge treatment areas, focusing on international frontier circular RNA (circRNA) technology. This funding round was led by MSA Capital and a renowned industri

  • Cancel
    Date：2022-06

    Exclusive Financial Advisor to the founders of Taikang Bybo Dental

  • Cancel
    Date：2022-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=730

    Sihuan Pharm announced that its non-wholly-owned subsidiary, Huisheng Pharm, has completed a RMB 500 million Series A financing. This round was invested by China Life Chengda (Shanghai) Health Industry Equity Investment Centre (L.P.), GF Investment, GF In

  • Cancel
    Date：2022-05
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=731

    Senlang Biotechnology announced the successful closing of RMB 200 million from Qianhai Ark Asset Management. CEC Capital Group acted as the exclusive financial advisor for Senlang Biotechnology in this transaction.

  • Cancel
    Date：2022-05

    Exclusive Financial Advisor to DOBOSO

  • Cancel
    Date：2022-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=732

    Fosun Pharmaceutical recently announced that its subsidiary, YanengBIO, along with its existing shareholders, has entered into a relevant agreement with Yaneng Bioscience under CBridge Capital. Upon completion of the transaction, YanengBIO will transition